|
|
 |
|
|
|
Components
| AbbVie Inc. |
ABBV |
| ACADIA Pharmaceuticals Inc. |
ACAD |
| ADMA Biologics, Inc. |
ADMA |
| Akero Therapeutics, Inc. |
AKRO |
| Alkermes Plc |
ALKS |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
| Amgen Inc. |
AMGN |
| Amneal Pharmaceuticals, Inc. |
AMRX |
| Axsome Therapeutics, Inc. |
AXSM |
| Biogen Inc. |
BIIB |
| BioMarin Pharmaceutical Inc. |
BMRN |
| Blueprint Medicines Corporation |
BPMC |
| Bristol-Myers Squibb Company |
BMY |
| Cardinal Health, Inc. |
CAH |
| Catalyst Pharmaceuticals, Inc. |
CPRX |
| Charles River Laboratories International, Inc. |
CRL |
| Corcept Therapeutics Inc. |
CORT |
| Elanco Animal Health Incorporated |
ELAN |
| Eli Lilly and Company |
LLY |
| Exact Sciences Corporation |
EXAS |
| Exelixis, Inc. |
EXEL |
| Gilead Sciences, Inc. |
GILD |
| Guardant Health, Inc. |
GH |
| Halozyme Therapeutics, Inc. |
HALO |
| Illumina, Inc. |
ILMN |
| Incyte Corporation |
INCY |
| Insmed Incorporated |
INSM |
| Jazz Pharmaceuticals Plc |
JAZZ |
| Johnson & Johnson |
JNJ |
| Krystal Biotech, Inc. |
KRYS |
| Madrigal Pharmaceuticals, Inc. |
MDGL |
| Medpace Holdings, Inc. |
MEDP |
| Merck & Co., Inc. |
MRK |
| Neurocrine Biosciences, Inc. |
NBIX |
| Organon & Co. |
OGN |
| Perrigo Company Plc |
PRGO |
| Pfizer Inc. |
PFE |
| Prestige Consumer Healthcare Inc. |
PBH |
| PTC Therapeutics, Inc. |
PTCT |
| Regeneron Pharmaceuticals, Inc. |
REGN |
| Sarepta Therapeutics, Inc. |
SRPT |
| Scholar Rock Holding Corporation |
SRRK |
| SpringWorks Therapeutics, Inc. |
SWTX |
| TG Therapeutics, Inc. |
TGTX |
| United Therapeutics Corporation |
UTHR |
| Veracyte, Inc. |
VCYT |
| Vericel Corporation |
VCEL |
| Vertex Pharmaceuticals Incorporated |
VRTX |
| Viatris Inc. |
VTRS |
| Zoetis Inc. |
ZTS |
|
|
|
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|